This page shows the latest Ionis news and features for those working in and with pharma, biotech and healthcare.
GlaxoSmithKline has announced positive results from a phase 2a study of its Ionis-partnered antisense medicine for chronic hepatitis B virus (CHB) infection. ... As part of the licensing deal, Ionis is set to receive fees and milestone payments of up to
In the ATTR polyneuropathy indication it has competition from Alnylam’s injectable drugs Onpattro (patisiran) and Ionis’ Tegsedi (inotersen), which were approved for that use in Europe in 2018.
Other competitors in the KRAS inhibitor race include Mirati, Boehringer Ingelheim, Johnson &Johnson/Wellspring and AstraZeneca/Ionis.
payout. . The drug – IONIS-MAPTRx – is an antisense therapy designed to reduce production of microtubule-associated protein tau (MAPT) or tau in the central nervous system. ... In pre-clinical research, IONIS-MAPTRx demonstrated prevention of
Has potential in cardiovascular and metabolic diseases. Pfizer has bolted on an antisense drug with potential in cardiovascular and metabolic diseases to its pipeline via a licensing deal with Ionis’ Akcea ... Founded in 2015, Akcea spun out of Ionis
There’s still plenty in the neuroscience pipeline however, including tofersen for amyotrophic lateral sclerosis (ALS) which stems from an alliance with antisense specialist Ionis and is due for a phase
More from news
Approximately 17 fully matching, plus 32 partially matching documents found.
Standing in its way is a similarly priced antisense rival from Ionis and Akcea – Tegsedi (inotersen) – as well as Pfizer’s fast- growing Vyndaqel/Vyndamax (tafamidis), which is approved for hATTR
The big biotech is testing its own BIIB092 in early Alzheimer’s patients and has an option to develop an Ionis Pharmaceuticals’ antisense drug designed to reduce production of tau in
Joint development using SQZ’s cell therapy. platform. $1.375B. Option. Ionis. RNA‐targeted therapeutics for complement mediated. ... RNA‐targeted therapeutic, IONIS‐FB‐LRx targeting Factor. B, for Geographic Atrophy, an advanced form of dry
While Onpattro has outshone Ionis’ product in safety and efficacy, analysts see Onpattro’s lack of cardiovascular claims in its US label as a weak point. ... England’s NICE is just beginning its review of Onpattro (in tandem with a review of
Since March 2018 Roche, with Ionis, have added another PRIME drug to their portfolio. ... RG6042 (formerly named IONIS-HTTRx) is in development for Huntington’s disease.
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...